Skip to main content
Erschienen in: Head and Neck Pathology 4/2018

14.12.2017 | Original Paper

LEF-1 is a Sensitive Marker of Cribriform Morular Variant of Papillary Thyroid Carcinoma

verfasst von: Shalini Mohindra, Hany Sakr, Charles Sturgis, Deborah J. Chute

Erschienen in: Head and Neck Pathology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Cribriform morular variant of PTC (CMV-PTC) frequently shows activation of the CTNNB1/Wnt pathway with nuclear accumulation of beta catenin. The utility of LEF-1, also in the CTNNB1/WNT pathway, in the diagnosis of CMV-PTC has not been previously studied. LEF-1 immunohistochemistry was performed on seven CMV-PTC, 52 benign cases and 101 malignant thyroid neoplasms. LEF-1 was scored by stain intensity (0 = no nuclear stain, 1 = weak nuclear stain, less than lymphocyte and 2 = strong nuclear stain, intense as lymphocyte) and percentage of positive cells at each intensity, for a maximum total score of 200. Sensitivity and specificity of LEF-1 stain for all cases and to differentiate between regular PTC and CMV-PTC was also calculated. Six of the seven CMV-PTCs showed ≥ 30% strong (2+) nuclear LEF-1 staining and a total score over 100. Beta catenin also showed strong and diffuse nuclear staining in these cases. One CMV-PTC was negative for both LEF-1 and beta catenin and did not have a history of FAP. All control PTC cases uniformly lacked LEF-1 staining at 2+ intensity. LEF-1 had a sensitivity of 86% and specificity of 98% for the diagnosis of CMV-PTC. LEF-1 is highly sensitive and specific marker for CMV-PTC, especially when used in the setting of a PTC neoplasm. The pattern of staining is important with ≥ 30% of cells showing strong 2+ nuclear staining having the highest combined sensitivity and specificity.
Literatur
1.
Zurück zum Zitat Pradhan D, Sharma A, Mohanty SK. Cribriform-morular variant of papillary thyroid carcinoma. Pathol Res Pract. 2015;211(10):712–6.CrossRefPubMed Pradhan D, Sharma A, Mohanty SK. Cribriform-morular variant of papillary thyroid carcinoma. Pathol Res Pract. 2015;211(10):712–6.CrossRefPubMed
2.
Zurück zum Zitat Harach HR, Williams GT, Williams ED. Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm. Histopathology. 1994;25(6):549–61.CrossRefPubMed Harach HR, Williams GT, Williams ED. Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm. Histopathology. 1994;25(6):549–61.CrossRefPubMed
3.
Zurück zum Zitat Cameselle-Teijeiro J, Chan JK. Cribriform-morular variant of papillary carcinoma: a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma? Mod Pathol. 1999;12(4):400–11.PubMed Cameselle-Teijeiro J, Chan JK. Cribriform-morular variant of papillary carcinoma: a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma? Mod Pathol. 1999;12(4):400–11.PubMed
4.
Zurück zum Zitat Boonyaarunnate T, Olson MT, Bishop JA, Yang GC, Ali SZ. Cribriform morular variant of papillary thyroid carcinoma: clinical and cytomorphological features on fine-needle aspiration. Acta Cytol. 2013;57(2):127–33.CrossRefPubMed Boonyaarunnate T, Olson MT, Bishop JA, Yang GC, Ali SZ. Cribriform morular variant of papillary thyroid carcinoma: clinical and cytomorphological features on fine-needle aspiration. Acta Cytol. 2013;57(2):127–33.CrossRefPubMed
5.
Zurück zum Zitat Levy RA, Hui VW, Sood R, Fish S, Markowitz AJ, Wong RJ, et al. Cribriform-morular variant of papillary thyroid carcinoma: an indication to screen for occult FAP. Fam Cancer. 2014;13(4):547–51.CrossRefPubMed Levy RA, Hui VW, Sood R, Fish S, Markowitz AJ, Wong RJ, et al. Cribriform-morular variant of papillary thyroid carcinoma: an indication to screen for occult FAP. Fam Cancer. 2014;13(4):547–51.CrossRefPubMed
6.
Zurück zum Zitat Jung CK, Choi YJ, Lee KY, Bae JS, Kim HJ, Yoon SK, et al. The cytological, clinical, and pathological features of the cribriform-morular variant of papillary thyroid carcinoma and mutation analysis of CTNNB1 and BRAF genes. Thyroid. 2009;19(8):905–13.CrossRefPubMed Jung CK, Choi YJ, Lee KY, Bae JS, Kim HJ, Yoon SK, et al. The cytological, clinical, and pathological features of the cribriform-morular variant of papillary thyroid carcinoma and mutation analysis of CTNNB1 and BRAF genes. Thyroid. 2009;19(8):905–13.CrossRefPubMed
7.
Zurück zum Zitat Kaya S, Gumus M, Gurbuz Y, Cabuk D, Acikgoz O, Temiz S, et al. The prognostic value of beta-catenin and LEF-1 expression in patients with operable gastric carcinoma. Am J Transl Res. 2016;8(2):1228–36.PubMedPubMedCentral Kaya S, Gumus M, Gurbuz Y, Cabuk D, Acikgoz O, Temiz S, et al. The prognostic value of beta-catenin and LEF-1 expression in patients with operable gastric carcinoma. Am J Transl Res. 2016;8(2):1228–36.PubMedPubMedCentral
8.
Zurück zum Zitat Tandon B, Peterson L, Gao J, Nelson B, Ma S, Rosen S, et al. Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas. Mod Pathol. 2011;24(11):1433–43.CrossRefPubMed Tandon B, Peterson L, Gao J, Nelson B, Ma S, Rosen S, et al. Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas. Mod Pathol. 2011;24(11):1433–43.CrossRefPubMed
9.
Zurück zum Zitat Singhi AD, Lilo M, Hruban RH, Cressman KL, Fuhrer K, Seethala RR. Overexpression of lymphoid enhancer-binding factor 1 (LEF1) in solid-pseudopapillary neoplasms of the pancreas. Mod Pathol. 2014;27(10):1355–63.CrossRefPubMedPubMedCentral Singhi AD, Lilo M, Hruban RH, Cressman KL, Fuhrer K, Seethala RR. Overexpression of lymphoid enhancer-binding factor 1 (LEF1) in solid-pseudopapillary neoplasms of the pancreas. Mod Pathol. 2014;27(10):1355–63.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Bilodeau EA, Acquafondata M, Barnes EL, Seethala RR. A comparative analysis of LEF-1 in odontogenic and salivary tumors. Hum Pathol. 2015;46(2):255–9.CrossRefPubMed Bilodeau EA, Acquafondata M, Barnes EL, Seethala RR. A comparative analysis of LEF-1 in odontogenic and salivary tumors. Hum Pathol. 2015;46(2):255–9.CrossRefPubMed
11.
Zurück zum Zitat Kermanshahi TR, Jayachandran P, Chang DT, Pai R. LEF-1 is frequently expressed in colorectal carcinoma and not in other gastrointestinal tract adenocarcinomas: an immunohistochemical survey of 602 gastrointestinal tract neoplasms. Appl Immunohistochem Mol Morphol. 2014;22(10):728–34.CrossRefPubMed Kermanshahi TR, Jayachandran P, Chang DT, Pai R. LEF-1 is frequently expressed in colorectal carcinoma and not in other gastrointestinal tract adenocarcinomas: an immunohistochemical survey of 602 gastrointestinal tract neoplasms. Appl Immunohistochem Mol Morphol. 2014;22(10):728–34.CrossRefPubMed
12.
Zurück zum Zitat Kurihara K, Shimizu S, Chong J, Hishima T, Funata N, Kashiwagi H, et al. Nuclear localization of immunoreactive beta-catenin is specific to familial adenomatous polyposis in papillary thyroid carcinoma. Jpn J Cancer Res. 2000;91(11):1100–2.CrossRefPubMedPubMedCentral Kurihara K, Shimizu S, Chong J, Hishima T, Funata N, Kashiwagi H, et al. Nuclear localization of immunoreactive beta-catenin is specific to familial adenomatous polyposis in papillary thyroid carcinoma. Jpn J Cancer Res. 2000;91(11):1100–2.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Hirokawa M, Maekawa M, Kuma S, Miyauchi A. Cribriform-morular variant of papillary thyroid carcinoma–cytological and immunocytochemical findings of 18 cases. Diagn Cytopathol. 2010;38(12):890–6.CrossRefPubMed Hirokawa M, Maekawa M, Kuma S, Miyauchi A. Cribriform-morular variant of papillary thyroid carcinoma–cytological and immunocytochemical findings of 18 cases. Diagn Cytopathol. 2010;38(12):890–6.CrossRefPubMed
14.
Zurück zum Zitat Koo JS, Jung W, Hong SW. Cytologic characteristics and beta-catenin immunocytochemistry on smear slide of cribriform-morular variant of papillary thyroid carcinoma. Acta Cytol. 2011;55(1):13 – 8.CrossRefPubMed Koo JS, Jung W, Hong SW. Cytologic characteristics and beta-catenin immunocytochemistry on smear slide of cribriform-morular variant of papillary thyroid carcinoma. Acta Cytol. 2011;55(1):13 – 8.CrossRefPubMed
15.
Zurück zum Zitat Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4(7):844–7.CrossRefPubMed Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4(7):844–7.CrossRefPubMed
16.
Zurück zum Zitat Garcia-Rostan G, Tallini G, Herrero A, D’Aquila TG, Carcangiu ML, Rimm DL. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res. 1999;59(8):1811–5.PubMed Garcia-Rostan G, Tallini G, Herrero A, D’Aquila TG, Carcangiu ML, Rimm DL. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res. 1999;59(8):1811–5.PubMed
Metadaten
Titel
LEF-1 is a Sensitive Marker of Cribriform Morular Variant of Papillary Thyroid Carcinoma
verfasst von
Shalini Mohindra
Hany Sakr
Charles Sturgis
Deborah J. Chute
Publikationsdatum
14.12.2017
Verlag
Springer US
Erschienen in
Head and Neck Pathology / Ausgabe 4/2018
Elektronische ISSN: 1936-0568
DOI
https://doi.org/10.1007/s12105-017-0873-3

Weitere Artikel der Ausgabe 4/2018

Head and Neck Pathology 4/2018 Zur Ausgabe

Sine qua non Radiology-Pathology

Juvenile Trabecular Ossifying Fibroma

Neu im Fachgebiet Pathologie